On August 1, 2024, Risen Pharma signed a comprehensive strategic cooperation agreement with the Shanghai Center for Infectious and Immunological Innovation to strengthen drug development cooperation in the field of infectious diseases. Both parties will fully leverage their respective resource advantages to enhance research and development cooperation in the areas of small molecule, small nucleic acid, and gene editing drugs for the treatment of infectious diseases, and jointly promote industrial and research progress and development. This comprehensive strategic cooperation in research and development not only brings new development opportunities for both parties but also injects new vitality into the global field of infectious diseases. It is believed that with the joint efforts of both parties, more significant scientific research achievements can be achieved.